QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) All Versions of this Article: mol.107.040568v1 72/6/1406    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nevin, S. T. Articles by Adams, D. J. Search for Related Content PubMed PubMed Citation Articles by Nevin, S. T. Articles by Adams, D. J.

Accelerated Communication

Are 910 Nicotinic Acetylcholine Receptors a Pain Target for -Conotoxins?

School of Biomedical Sciences (S.T.N., D.J.A.) and the Institute for Molecular Bioscience (R.J.C., D.J.C.), the University of Queensland, Brisbane, Queensland, Australia; and Pain Management Research Institute, Kolling Institute, University of Sydney at Royal North Shore Hospital, St. Leonards, New South Wales, Australia (H.K., M.J.C.)

Received August 3, 2007; accepted September 5, 2007

	Abstract

Top Abstract Materials and Methods Results Discussion References

 
The synthetic -conotoxin Vc1.1 is a small disulfide bonded peptide currently in development as a treatment for neuropathic pain. Unlike Vc1.1, the native post-translationally modified peptide vc1a does not act as an analgesic in vivo in rat models of neuropathic pain. It has recently been proposed that the primary target of Vc1.1 is the 910 nicotinic acetylcholine receptor (nAChR). We show that Vc1.1 and its post-translationally modified analogs vc1a, [P6O]Vc1.1, and [E14]Vc1.1 are equally potent at inhibiting ACh-evoked currents mediated by 910 nAChRs. This suggests that 910 nAChRs are unlikely to be the molecular mechanism or therapeutic target of Vc1.1 for the treatment of neuropathic pain.

	Materials and Methods

Top Abstract Materials and Methods Results Discussion References

 
Peptide Synthesis and Oxidative Folding. Vc1.1, vc1a, [P6O]Vc1.1, and [E14]Vc1.1 were synthesized by manual solidphase peptide synthesis on 4-methylbenzhydryl amine amide resin using the in situ neutralization/O-benzotriazole-N,N,N',N'-tetramethyluronium protocol for Boc chemistry (Schnölzer et al., 1992). Cleavage of the peptides from the resin was achieved using HF with p-cresol and p-thiocresol as scavengers [9:0.5:0.5 (v/v) HF:p-cresol:p-thiocresol]. The reaction was allowed to proceed at -5 to 0°C for 1.5 h. The HF was then removed under vacuum, and the peptides were precipitated with ether, filtered, dissolved in 50% acetonitrile containing 0.05% TFA, and lyophilized. The crude peptides were purified by RP-HPLC on a C₁₈ (Phenomenex, Torrance, CA) column using a gradient of 0 to 80% B (buffer A, H₂O and 0.05% TFA; buffer B, 90% CH₃CN, 10% H₂O, and 0.045% TFA) in 80 min, and the eluent was monitored at 230 nm. These conditions were used in subsequent purification steps. Analytical RP-HPLC and ES-MS confirmed the purity and molecular mass of the synthesized peptides. The linear peptides were oxidized by dissolving in 0.1 M NH₄HCO₃, pH 8.2, at a concentration of 0.3 mg/ml and stirring overnight at room temperature. The oxidized peptides were then purified by RP-HPLC and the molecular mass confirmed by ES-MS. All four peptides, Vc1.1, vc1a, [P6O]Vc1.1, and [E14]Vc1.1, formed almost exclusively a single isomer with a monoisotopic molecular mass of 1809.7, 1866.6, 1821.6, and 1850.9 Da, respectively, as determined by ES-MS (see Clark et al., 2006).

NMR Spectroscopy. NMR data for Vc1.1, vc1a, [P6O]Vc1.1, and [E14]Vc1.1 were recorded on samples dissolved in 90% H₂O/10% D₂O at pH 3.5. ARX 500 and 600 MHz spectrometers (Bruker, Karlsrühe, Germany) were used in the acquisition of data. Two-dimensional NMR experiments included double quantum filtered-correlation spectroscopy, two-dimensional total correlation spectroscopy, and nuclear Overhauser effect spectroscopy, with all spectra recorded at 280 K. All spectra were analyzed on Indigo workstations (SGI, Mountain View, CA) using XWINNMR 1.3 (Bruker) and Sparky software. Chemical shifts were referenced to 2,2-dimethyl-2-silapentane-5-sulfonate sodium salt at 0 ppm.

Electrophysiological Recordings from nAChRs Exogenously Expressed in Xenopus laevis Oocytes. RNA preparation, oocyte preparation, and expression of nAChR subunits in X. laevis oocytes were performed as described previously (Clark et al., 2006). Plasmids with cDNA encoding the rat 9 and 10 nAChR subunits were kindly provided by Dr. A. B. Elgoyhen (Universidad de Buenos Aires, Buenos Aires, Argentina). All oocytes were injected with 1 to 5 ng of cRNA and then kept at 18°C in ND96 buffer (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl₂, 1 mM MgCl₂ and 5 mM HEPES at pH 7.4) supplemented with 50 mg/liter gentamicin and 5 mM pyruvic acid 2 to 5 days before recording.

Membrane currents were recorded from X. laevis oocytes using an automated workstation with eight channels in parallel, including drug delivery and on-line analysis (OpusXpress 6000A workstation; Molecular Devices, Sunnyvale, CA). Both the voltage recording and current injecting electrodes were pulled from borosilicate glass (Harvard Apparatus Ltd., Edenbridge, UK) and had resistances of 0.3 to 1.5 M when filled with 3 M KCl. All recordings were conducted at room temperature (20–23°C) using a bath solution of ND96 as described above. During recordings, the oocytes were perfused continuously at a rate of 1.5 ml/min, with 300-s incubation times for the conotoxin. Acetylcholine (ACh; 30 µM) was applied for 2 s at 5 ml/min, with 600-s washout periods between applications. Conopeptides were bath applied and coapplied with the agonist. Cells were voltage-clamped at a holding potential of -80 mV. Data were sampled at 500 Hz and filtered at 200 Hz. Peak current amplitude was measured before and after incubation of the peptide.

Neuropathic Pain Was Assessed Using Partial Ligation of the Left Sciatic Nerve (PNL). (Seltzer et al., 1990). In brief, the left sciatic nerve in the mid-thigh region of male Sprague-Dawley rats (250–300 g) was exposed by blunt dissection through the biceps femoris. A 4-0 silk thread was inserted into the left sciatic nerve trunk approximately 3 mm proximal to the trifurcation of the nerve at the popliteal fossa and was tightly ligated so that 30 to 50% of the dorsal nerve thickness was trapped in the ligature.

The effects of the conotoxins on withdrawal thresholds and motor function were assessed between 12 and 16 days after PNL in all animals. On the day of drug testing, animals were tested twice before injection (30 min before and immediately before injection) to stabilize preinjection responses and then at 1, 2, and 4 h after injection. Conotoxins were injected in a normal saline vehicle (0.2 ml per animal) intramuscularly in the vicinity of the nerve injury. Mechanical paw withdrawal thresholds (PWT) were measured using a series of von Frey filaments with bending pressures ranging from 0.41 to 15.1 g. Rats were placed in elevated plastic cages with wire mesh bases. All rats were given 30 min to acclimate to the testing environment. Beginning with the 2 g filament, von Frey hairs were pressed perpendicularly against the plantar surface of the left hind paw and held for 2 s. Each von Frey filament was applied seven times at random locations. A positive response was regarded as the sharp withdrawal of the paw, licking of the paw, or flinching upon removal of the von Frey filament.

The mechanical PWT was calculated using the up-down paradigm (Chaplan et al., 1994). If the animals responded to all or did not respond to any hairs then the mechanical PWT was assigned as 0.2 or 15 g, respectively. The tester was blind to all treatments.

Statistics. Concentration-response curves for antagonists were fitted by unweighted nonlinear regression to the logistic equation

where E_x is the response, X is the antagonist concentration, E_max is the maximal response, n_H is the slope factor, and IC₅₀ is the concentration of antagonist that gives 50% inhibition of the agonist response. All electrophysiological data were pooled (n = 3–7 for each data point) and represent arithmetic means ± standard error of the fit. Computation was done using SigmaPlot 9.0 (Systat Software, Point Richmond, CA). Statistical comparisons of mechanical PWT over time were made using a two-way analysis of variance (analysis of variance, using time and drug treatment as within- and between-subjects factors), with post hoc comparisons over time for individual drug treatment groups using Sidak's adjustment for multiple comparisons (SPSS Inc., Chicago, IL).

	Results

Top Abstract Materials and Methods Results Discussion References

 
Sequences and Structural Comparison of -conotoxin Vc1.1 and Its Post-Translationally Modified Analogs. In this study, we synthesized -conotoxin Vc1.1, the post-translationally modified native peptide vc1a, and the intermediate analogs [P6O]Vc1.1 and [E14]Vc1.1 and compared their structures and selectivity for nAChR subtypes. The sequences and disulfide connectivity are shown in Fig. 1. [P6O]Vc1.1 and [E14]Vc1.1, which contain either a hydroxyproline in position 6ora -carboxyglutamate at position 14, respectively, together with the unmodified peptide Vc1.1 and the fully modified vc1a, provide the full complement of analogs to determine the role of the post-translationally modified residues on activity.

View larger version (12K): [in this window] [in a new window]   Fig. 1. The sequences of Vc1.1, vc1a, [P6O]Vc1.1, and [E14]Vc1.1. Positions subject to modification are highlighted in light gray; hydroxyproline and -carboxyglutamic acid are represented in bold. The CysI-CysIII and CysII-CysIV disulfide bonds are indicated, and the loops between CysII and CysIII and CysIII and CysIV are named Loops 1 and 2, respectively. *, C-terminal amidation.

Vc1.1, vc1a, [P6O]Vc1.1, and [E14]Vc1.1 were found to fold efficiently into the predominant "globular" isomer, which has a I-III, II-IV disulfide connectivity common to all -conotoxins (Fig. 2A). Figure 2B shows a comparison of the NMR H secondary shifts for the four peptides. This analysis reveals that they are almost identical in structure; the only chemical shift changes occur where there is a change in residue type at positions 6 and/or 14. This similarity in structure is reinforced by the fact the H secondary shift for [P6O]Vc1.1 matches vc1a at position 6 (because both share a hydroxyproline at this position) and matches Vc1.1 at position 14 (both Glu), and the reverse is the case for [E14]Vc1.1. In addition, the chemical shift differences between the H protons of the side chains of comparable residues in each molecule are also similar, suggesting that the side chain orientations in all four peptides are also very similar (see Fig. 2C). Therefore, any differences in the biological targets of these peptides are not due to major changes in the three-dimensional shape of the molecules.

View larger version (28K): [in this window] [in a new window]   Fig. 2. Structural comparison of Vc1.1 and its post-translationally modified analogs. A, the three dimensional structure of Vc1.1 showing the -helical region and "globular" disulfide connectivity: CysI-CysIII and CysII-CysIV. The side chains of Pro6 (green) and Glu14 (red), the two residues subject to modification, are highlighted. B, the H secondary shifts for Vc1.1 (blue), vc1a (red), [P6O]Vc1.1 (green), and [E14]Vc1.1 (purple). The peptides have almost identical secondary shifts, indicating that the structures are very similar. The changes highlighted by the arrows and boxes for Pro/Hyp6 and Glu/Gla14 are local effects confined to the points of substitution. C, H chemical shift differences for Vc1.1 (blue), vc1a (red), [P6O]Vc1.1 (green), and [E14]Vc1.1 (purple). Values for Gly1 and Ile15 are not shown because they do not have two protons. The similarity in most values for all four molecules suggests that the side chains are in comparable orientations. The boxes highlight the H chemical shift differences for the modified residues. As for the H secondary shifts, there is a pairing of the trends based on the residue type at positions 6 or 14.

Inhibition of rat 910 nAChRs Expressed in X. laevis Oocytes by Vc1.1 and its Post-Translationally Modified Analogs. Vc1.1 has been shown previously to inhibit 3-containing nAChRs but only at micromolar concentrations, and it was inactive at concentrations up to 10 µM at 7, 4-containing, and muscle (11) nAChRs expressed in oocytes (Clark et al., 2006). The potency and selectivity of Vc1.1, vc1a, [P6O]Vc1.1, and [E14]Vc1.1 were investigated for their effects on ACh-evoked membrane currents in X. laevis oocytes expressing various nAChRs subunit combinations. Vc1.1 has been shown to act as a competitive antagonist at nAChRs in bovine chromaffin cells (Clark et al., 2006), and in oocytes, raising the ACh concentration to 100 µM shifted the Vc1.1 concentration-response curve to the right compared with 30 µM ACh (data not shown). We examined the effects of Vc1.1, vc1a, [P6O]Vc1.1, and [E14]Vc1.1 on 910 nAChRs expressed in X. laevis oocytes. Globular Vc1.1 reversibly inhibited 910 nAChR-mediated currents in a concentration-dependent manner with an IC₅₀ of 64.2 ± 15.0 nM (n = 12) (Fig. 3A), whereas the ribbon isomer (i.e., I-IV, II-III disulfide connectivity) was inactive at concentrations up to 10 µM (n = 4). Application of vc1a, [P6O]Vc1.1, and [E14]Vc1.1 also inhibited reversibly 910 nAChRs in a concentration-dependent manner, giving IC₅₀ values of 62.9 ± 5.2, 99.1 ± 29.7, and 65.3 ± 14.9 nM (n = 10–11), respectively (Fig. 3B). The inhibition of ACh-evoked currents mediated by 910 nAChRs was complete at peptide concentrations 1 µM, in contrast to that observed for other nAChR subunit combinations (Clark et al., 2006), and the Hill coefficients indicate a unitary toxin/receptor stoichiometry (Table 1).

View larger version (18K): [in this window] [in a new window]   Fig. 3. Inhibition of rat 910 nAChRs expressed in X. laevis oocytes by Vc1.1 and its post-translationally modified analogs vc1a, [P6O]Vc1.1, and [E14]Vc1.1. A, representative superimposed traces of ACh-evoked currents in the absence (solid line) and presence Vc1.1 and vc1a (broken lines). Oocytes were voltage-clamped at -80 mV, and membrane currents were evoked with 30 µM ACh in the absence and presence of the peptide. B, concentration-response curves obtained for the inhibition of ACh-evoked current amplitude after 300-s incubation of Vc1.1 and its analogs, Vc1.1 (), vc1a (), [P6O]Vc1.1 (gray ), and [E14]Vc1.1 (gray ). Concentration-response data for the antagonists were fit using the logistic equation from Materials and Methods.

View this table: [in this window] [in a new window]   TABLE 1 Inhibition of recombinant 910 nAChR subunits expressed in X. laevis oocytes by Vc1.1 and post-translationally modified peptides Membrane currents evoked with 30 µM ACh; pooled data (n = 3–7 for each data point) for curve fitting.

Intramuscular Injection of -Conotoxin Vc1.1, but Not vc1a or [P6O]Vc1.1, Relieves Mechanical Allodynia in a Nerve Injury Model of Neuropathic Pain. PNL produced a profound reduction in paw withdrawal threshold from a presurgery baseline of 12.9 ± 0.7 to 0.7 ± 0.1g(n = 33) 12 to 16 days after surgery (see Fig. 4). As reported previously (Satkunanathan et al., 2005), intramuscular injection of 60 µg of Vc1.1 produced significant partial reversal of allodynia associated with nerve injury (Fig. 4). By contrast, injections of high doses of vc1a or [P6O]Vc1.1 (60 µg/rat each) had no effect on mechanical allodynia. The small apparent (nonsignificant) increase in withdrawal threshold observed 4 h after administration of [P6O]Vc1.1 suggests that this analog may produce a delayed antiallodynic effect compared with Vc1.1. At present, we cannot exclude the possibility that a delayed effect of this analog of Vc1.1 is due to reduced bioavailability.

View larger version (14K): [in this window] [in a new window]   Fig. 4. Intramuscular injection of -conotoxin Vc1.1 (60 µg) () relieves mechanical allodynia in a nerve injury model of neuropathic pain but vc1a () and [P6O]Vc.1.1 () are both inactive at high doses (60 µg/rat). A, time-response relationship of mechanical paw withdrawal response. **, p < 0.002 for Vc1.1 versus baseline, n = 6–11 animals per group. B, area under the curve for the antiallodynic effect; **, p < 0.001 for Vc1.1.

	Discussion

Top Abstract Materials and Methods Results Discussion References

A comparison of the NMR chemical shifts for vc1a, [P6O]Vc1.1, and [E14]Vc1.1 with those for Vc1.1 showed that the post-translationally modified analogs are structurally analogous to Vc1.1, and therefore variations in biological activity between these peptides are due to the side-chain modifications and not a structural perturbation. Substitution of Pro6 in Vc1.1 to hydroxyproline in [P6O]Vc1.1 results in a loss of activity at 3-containing nAChR subtypes (Clark et al., 2006), but the current study shows that activity at the 910 nAChR subtype is not negated by this mutation. The crystal structure of the -conotoxin ImI, which has a loop 1 identical to that of Vc1.1, in complex with acetylcholine binding protein (AChBP), a soluble homolog of the ligand binding domain of the nAChR, has been reported (Ulens et al., 2006). This structure revealed that Pro6 in ImI makes van der Waals contacts with Tyr53 and Ile116 of the AChBP. The 3 nAChR subunit also has an Ile at the position corresponding to Ile116 in the AChBP. Therefore, it seems likely that a hydroxyproline in position 6 of the conotoxin could disrupt key hydrophobic interactions with the 3 subunit. In contrast, in both the 9 and 10 nAChR subtypes, the residue corresponding to Ile116 is an aspartic acid. Therefore, mutation of Pro6 in Vc1.1 to hydroxyproline may be counteracted by interactions between the new hydroxyl group and the aspartic acid in the 9 and 10 subunits. This is further supported by work that found that substitution of Pro6 with Hyp in -conotoxin PnIB caused a dramatic reduction in activity on the 7 nAChR subtype (Quiram et al., 2000). The 7 nAChR subtype also has a hydrophobic residue (leucine) at the position corresponding to Ile116 in the AChBP. The mutation of Glu14 to a -carboxyglutamic acid is a more conservative residue change, so it is not surprising that it has little effect on activity. In addition, the crystal structures of -conotoxins with the AChBP show that this residue is more solvent exposed and is less important for receptor interactions.

In conclusion, synthetic vc1a and the partially modified homologs [P6O]Vc1.1 and [E14]Vc1.1 are all active at 910 nAChRs but not at any of the other nAChR subtypes studied (Clark et al., 2006). Recent studies of -conotoxins Vc1.1 and RgIA have also attributed the acute analgesia produced by these conotoxins to the antagonism of 910 nAChRs (Ellison et al., 2006; Vincler et al., 2006; Vincler and McIntosh, 2007). However, given that Vc1.1, but not vc1a or its analog [P6O]Vc1.1, was able to inhibit a vascular response to pain and reduce chronic pain in several animal models of human neuropathy (Livett et al., 2002, 2006; Lang et al., 2005), it is highly unlikely that 910 nAChRs are the molecular mechanism or therapeutic target of Vc1.1 for the treatment of neuropathic pain.

	Footnotes

 
This work was supported by funding from the Australian Research Council (DP0208295) and National Health and Medical Research Council (NHMRC) (352446). M.J.C. is an NHMRC Senior Principal Research Fellow. D.J.C. is an Australian Research Council Professorial Fellow.

S.T.N. and R.J.C. contributed equally to this work.

Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.

doi:10.1124/mol.107.040568.

ABBREVIATIONS: nAChR, nicotinic acetylcholine receptor; MS, mass spectrometry; HF, hydrogen fluoride; TFA, trifluoroacetic acid; RP-HPLC, reversed-phase–high-performance liquid chromatography; ES-MS, electrospray-mass spectrometry; ACh, acetylcholine; PNL, partial ligation of the left sciatic nerve; PWT, paw withdrawal threshold; AChBP, acetylcholine binding protein.

Address correspondence to: David J. Adams, School of Biomedical Sciences, The University of Queensland, Brisbane, QLD 4072, Australia. E-mail: dadams{at}uq.edu.au

	References

Top Abstract Materials and Methods Results Discussion References

 
Chaplan SR, Bach FW, Pogrel JW, Chung JM, and Yaksh TL (1994) Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53: 55-63.[CrossRef][Medline]

Clark RJ, Fischer H, Nevin ST, Adams DJ, and Craik DJ (2006) The synthesis, structural characterization, and receptor specificity of the -conotoxin Vc1.1. J Biol Chem 281: 23254-23263.[Abstract/Free Full Text]

Dutton JL and Craik DJ (2001) -Conotoxins: Nicotinic acetylcholine receptor antagonists as pharmacological tools and potential drug leads. Curr Med Chem 8: 327-344.[Medline]

Ellison M, Haberlandt C, Gomez-Casati ME, Watkins M, Elgoyhen AB, McIntosh JM, and Olivera BM (2006) -RgIA: a novel conotoxin that specifically and potentially blocks the 910 nAChR. Biochemistry 45: 1511-1517.[CrossRef][Medline]

Jakubowski JA, Keays DA, Kelley WP, Sandall DW, Bingham JP, Livett BG, Gayler KR, and Sweedler JV (2004) Determining sequences and post-translational modifications of novel conotoxins in Conus victoriae using cDNA sequencing and mass spectroscopy. J Mass Spectrom 39: 548-557.[CrossRef][Medline]

Lang PM, Burgstahler R, Haberberger RV, Sippel W, and Grafe P (2005) A conus peptide blocks nicotinic receptors of unmyelinated axons in human nerves. Neuroreport 16: 479-483.[CrossRef][Medline]

Livett BG, Gayler KR, and Khalil Z (2004) Drugs from the sea: conopeptides as potential therapeutics. Curr Med Chem 11: 1715-1723.[Medline]

Livett B, Khalil Z, Gayler K, and Down J (2002), inventors and assignees. Alpha conotoxin peptides with analgesic properties. World Patent No. WO02079236. 2002 Oct 10.

Livett BG, Sandall DW, Keays D, Down J, Gayler KR, Satkunanathan N, and Khalil Z (2006) Therapeutic applications of conotoxins that target the neuronal nicotinic acetylcholine receptor. Toxicon 48: 810-829.[Medline]

McIntosh JM, Santos AD, and Olivera BM (1999) Conus peptides targeted to specific nicotinic acetylcholine receptor subtypes. Annu Rev Biochem 68: 59-88.[CrossRef][Medline]

Quiram PA, McIntosh JM, and Sine SM (2000) Pairwise interactions between neuronal 7 acetylcholine receptors and -conotoxin PnIB. J Biol Chem 275: 4889-4896.[Abstract/Free Full Text]

Sandall DW, Satkunanathan N, Keays DA, Polidano MA, Liping X, Pham V, Down JG, Khalil Z, Livett BG, and Gayler KR (2003) A novel -conotoxin identified by gene sequencing is active in suppressing the vascular response to selective stimulation of sensory nerves in vivo. Biochemistry 42: 6904-6911.[CrossRef][Medline]

Satkunanathan N, Livett B, Gayler K, Sandall D, Down J, and Khalil Z (2005) Alpha-conotoxin Vc1.1 alleviates neuropathic pain and accelerates functional recovery of injured neurones. Brain Res 1059: 149-158.[CrossRef][Medline]

Schnölzer M, Alewood P, Jones A, Alewood D, and Kent SB (1992) In situ neutralization in Boc-chemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult sequences. Int J Pept Protein Res 40: 180-193.[Medline]

Seltzer Z, Dubner R, and Shir Y (1990) A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 43: 205-218.[CrossRef][Medline]

Ulens C, Hogg RC, Celie PH, Bertrand D, Tsetlin V, Smit AB, and Sixma TK (2006) Structural determinants of selective -conotoxin binding to a nicotinic acetylcholine receptor homolog AChBP. Proc Natl Acad Sci U S A 103: 3615-3620.[Abstract/Free Full Text]

Vincler M, Wittenauer S, Parker R, Ellison M, Olivera BM, and McIntosh JM (2006) Molecular mechanism for analgesia involving specific antagonism of 910 nicotinic acetylcholine receptors. Proc Natl Acad Sci U S A 103: 17880-17884.[Abstract/Free Full Text]

Vincler M and McIntosh JM (2007) Targeting the 910 nicotinic acetylcholine receptor to treat severe pain. Expert Opin Ther Targets 11: 891-897.[CrossRef][Medline]

This article has been cited by other articles:

				E. L. Millard, S. T. Nevin, M. L. Loughnan, A. Nicke, R. J. Clark, P. F. Alewood, R. J. Lewis, D. J. Adams, D. J. Craik, and N. L. Daly Inhibition of Neuronal Nicotinic Acetylcholine Receptor Subtypes by {alpha}-Conotoxin GID and Analogues J. Biol. Chem., February 20, 2009; 284(8): 4944 - 4951. [Abstract] [Full Text] [PDF]

				B. Callaghan, A. Haythornthwaite, G. Berecki, R. J. Clark, D. J. Craik, and D. J. Adams Analgesic {alpha}-Conotoxins Vc1.1 and Rg1A Inhibit N-Type Calcium Channels in Rat Sensory Neurons via GABAB Receptor Activation J. Neurosci., October 22, 2008; 28(43): 10943 - 10951. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: mol.107.040568v1 72/6/1406    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nevin, S. T. Articles by Adams, D. J. Search for Related Content PubMed PubMed Citation Articles by Nevin, S. T. Articles by Adams, D. J.